Hers vs MyStart Health

Choose hers if: You are female with multiple health needs beyond weight loss - obesity + PCOS-related hair loss, obesity + depression/anxiety, obesity + hormonal skin issues - benefiting from coordinated women-specific medical care through integrated platform. You care what 7+ years of operating history and public-company status prove about treatment continuity. You want medication flexibility with both semaglutide and tirzepatide options enabling treatment optimization. You prioritize women's health expertise, multi-category coordination, and certainty over maximum cost minimization. You accept higher costs ($199-349/month) for balanced quality, care, and platform capabilities.

Choose MyStart Health if: You have extreme budget constraints where $360-1,560 annual savings critically matters as primary consideration outweighing other factors. You have straightforward medical history without complications unlikely to benefit from women's health expertise or multi-condition coordination. You can accept semaglutide-only formulary without need for tirzepatide option or medication alternatives. You are comfortable with brand-new unproven platform (launched 2023, <1 year history) accepting highest market risk including potential treatment disruption from supply failures or business instability. You serve any gender (universal access) needing exclusively lowest-price GLP-1 without women-specific services. You prioritize immediate maximum cost reduction over service integration, clinical depth, and treatment continuity.

Bottom line: hers and MyStart Health represent extreme opposite ends of the telehealth spectrum - hers offers full-spectrum women's health integration ($199-349/month) with 7+ years of proven service, multi-category coordination, female health expertise, dual GLP-1 formulary, and public company stability, serving female patients with multiple interconnected health concerns, while MyStart Health provides absolute minimum market pricing ($169-219/month) through ultra-budget newest-startup model (<1 year old), semaglutide-only restriction, minimal services, universal gender access, and maximum uncertainty creating elevated treatment disruption risk. For women with multiple health needs or medication flexibility requirements, hers delivers dramatically superior value through full expertise, established operations, treatment coordination, and certainty despite higher costs - the years behind it and the women's health integration justify the premium for patients who can afford moderate additional investment. For patients with extreme budget constraints accepting maximum risk, straightforward needs, and semaglutide-only acceptance, MyStart Health's meaningful savings ($360-1,560 annually) may justify trade-offs - though the unproven newest-platform status, zero track record, and ultra-budget economics present a notable gamble on treatment continuity unsuitable for patients requiring reliability certainty in chronic weight management requiring long-term medication access.